Physician profile
Justin Putz
NPI 1346864345
$3,782.93
in general payments reported to CMS, 2019-2025
22 companies · $3,707 in 2025
The $3,707 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.09 · 2023: $21.43 · 2024: $20.94 · 2025: $3,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990 · Consulting Fee: $1,700 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.85 |
| Consulting Fee | $1,700.00 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $1,854.98 | 2025 | |
| Janssen Biotech, INC. | $302.67 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $278.53 | 2021-2025 | Saphnelo |
| Amgen INC. | $277.80 | 2025 | Uplizna, Krystexxa, Evenity |
| Ucb, INC. | $231.64 | 2025 | Bimzelx |
| Abbvie INC. | $197.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $114.26 | 2025 | |
| Radius Health, INC. | $85.61 | 2025 | Tymlos |
| Organon LLC | $81.55 | 2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $57.01 | 2025 | Purified Cortrophin Gel |
| Tersera Therapeutics LLC | $50.31 | 2025 | Quzyttir |
| Genzyme Corporation | $43.28 | 2025 | |
| Alexion Pharmaceuticals, INC. | $33.01 | 2025 | Strensiq |
| Glaxosmithkline, LLC. | $25.35 | 2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $23.76 | 2025 | Orencia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.20 | 2025 | Gazyva |
| Novo Nordisk INC | $21.43 | 2023 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $20.94 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $19.68 | 2025 | |
| Janssen Scientific Affairs, LLC | $14.19 | 2025 | Tremfya |
| Csl Behring | $14.01 | 2025 | Hizentra |
| Mylan Specialty L.P. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Putz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.